9E
9EP.F Enanta Pharmaceuticals Inc
- Market cap
- EUR 290M
- P/E
- -
- P/B
- 3.24x
- ROE
- -58.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is 9EP.F undervalued?
Graham numberThe Graham number of Enanta Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Enanta Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Enanta Pharmaceuticals Inc yet.
Enanta Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the t…
Full company profileEnanta Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Enanta Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 88.3M | 103M | 207M | 205M | 122M | 97.1M | 86.2M | 79.2M | 67.6M | 65.3M | 66.8M |
| Gross Profit | 88.3M | 103M | 207M | 205M | - | - | - | - | - | - | - |
| Operating Income | 30.8M | 24.6M | 88.3M | 36.7M | -41.6M | -110M | -124M | -137M | -122M | -85.3M | -53.8M |
| EBITDA | - | 29.1M | 90.8M | 40.0M | -38.0M | - | -121M | -123M | -105M | -71.3M | -40.4M |
| Net Income | 21.7M | 17.7M | 72.0M | 46.4M | -36.2M | -79.0M | -122M | -134M | -116M | -81.9M | -59.4M |
| EPS | - | 0.93 | 3.71 | 2.35 | -1.80 | -3.90 | -5.86 | -6.35 | -5.48 | -3.83 | -2.04 |
| Balance Sheet | |||||||||||
| Total Assets | 281M | 327M | 414M | 490M | 486M | 439M | 375M | 462M | 377M | 281M | 297M |
| Total Liabilities | 11.3M | 25.0M | 20.5M | 27.3M | 30.6M | 39.4M | 54.1M | 246M | 248M | 216M | 196M |
| Shareholders' Equity | 270M | 302M | 394M | 462M | 456M | 399M | 321M | 217M | 129M | 64.7M | 101M |
| Cash & Short-term Investments | 16.6M | 65.7M | 63.9M | 51.2M | 87.1M | 57.2M | 44.0M | 85.4M | 37.2M | 32.3M | 33.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 35.8M | 52.7M | 29.2M | 71.4M | 7.09M | -70.0M | -84.8M | -103M | -78.8M | -19.3M | -38.4M |
| Capital Expenditure | 4.74M | 2.51M | 2.98M | 5.42M | 1.45M | 750K | 2.13M | 9.06M | 17.9M | 12.9M | 220K |
| Free Cash Flow | - | 50.1M | 26.2M | 66.0M | 5.64M | -70.7M | -86.9M | -112M | -96.7M | -32.2M | -38.7M |
| Ratios | |||||||||||
| ROE | 8.0% | 5.9% | 18.3% | 10.0% | -7.9% | -19.8% | -37.9% | -61.7% | -90.1% | -126.5% | -58.7% |
| ROA | 7.7% | 5.4% | 17.4% | 9.5% | -7.4% | -18.0% | -32.4% | -28.9% | -30.8% | -29.2% | -20.0% |
| Net Profit Margin | 24.5% | 17.2% | 34.8% | 22.6% | -29.5% | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% | -88.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Enanta Pharmaceuticals Inc dividends
Enanta Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Enanta Pharmaceuticals Inc
- Insiders 4.67%
- Institutions 93.45%
- Public & others 1.88%
- Shares outstanding 29.1M
- Free float 22.5M
Enanta Pharmaceuticals Inc company profile
- Company name
- Enanta Pharmaceuticals Inc
- Ticker
- 9EP.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 120
- Fiscal year end
- September
- Address
- 4 Kingsbury Avenue, Watertown, MA, United States, 02472
- Phone
- 617 607 0800
- Website
- enanta.com
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals Inc management
9- Dr. Jay R. Luly Ph.D.President, CEO & Director · born 1956
- Dr. Yat Sun Or Ph.D.Chief Scientific Officer · born 1952
- Dr. Scott T. Rottinghaus M.D.Chief Medical Officer · born 1974
- Mr. Harry R. Trout IIIVP of Finance & Interim Principal Financial Officer · born 1969
- Ms. Kathleen S. Capps CPAExecutive Director of Accounting, Controller & Interim Principal Accounting Officer · born 1985
- Ms. Jennifer VieraExecutive Director of Investor Relations & Corporate Communications
- Mr. Matthew P. Kowalsky J.D.Chief Legal Officer & Corporate Secretary · born 1973
- Mr. Nathaniel S. Gardiner J.D.Consultant · born 1954
- Mr. Brendan LuuChief Business Officer · born 1975